Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?

Benzer Materyaller

• Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
  Yazar:: Hyun Ae Jung, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-10-01)
• EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
  Yazar:: Park, Sehhoon, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
  Yazar:: Cho, Jang Ho, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study
  Yazar:: Ji Eun Shin, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-10-01)
• Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
  Yazar:: Kim, Hongsik, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)